Tirzepatide
Metabolic
A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Demonstrated up to 22.5% weight reduction.
MetabolicFat LossAppetite ControlInsulin SensitivityBlood Sugar ControlNauseaConstipationDiarrheaWeight LossSubcutaneous (SubQ)
Community
0
Tracking
0
Doses Logged
2.5mg/week
Common Dose
—
Adverse Rate
All dosages:2.5mg/week5mg/week7.5mg/week10mg/week15mg/week
Reported Adverse Effects
No adverse effects reported yet
Community Consensus
No consensus claims yet — be the first to contribute
Literature
No studies linked yet — know of one? Share it in the discussion
Discussion
No discussion yet — be the first to share your experience